(GMAB) Genmab AS - Performance -27.2% in 12m
Compare GMAB with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-43.48%
#66 in Group
Rel. Strength
22.20%
#6207 in Universe
Total Return 12m
-27.20%
#77 in Group
Total Return 5y
-14.47%
#43 in Group
P/E 11.2
45th Percentile in Group
P/E Forward 11.4
46th Percentile in Group
PEG 1.08
83th Percentile in Group
FCF Yield 11.8%
98th Percentile in Group
12m Total Return: GMAB (-27.2%) vs XBI (-5.4%)

5y Drawdown (Underwater) Chart

Top Performers in Biotechnology
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
UTHR NASDAQ United Therapeutics |
-4.25% | 15.2% | 163% | 12.1 | 10.6 | 1.43 | 81.5% | 18.5% |
HLN NYSE Haleon |
2.64% | 25.8% | 43.6% | 24.4 | 20.2 | 1.79 | 64.4% | 6.58% |
AMGN NASDAQ Amgen |
-7.54% | 5.43% | 43.3% | 38.5 | 13.8 | 0.97 | -42.0% | -25.9% |
LONN SW Lonza |
8.68% | 15.4% | 38.7% | 65.8 | 33.6 | 1.23 | 12.6% | -10.3% |
BIM PA Biomerieux |
2.77% | 21.2% | 8.84% | 31 | 24.2 | 1.45 | -58.7% | -25.1% |
KMDA NASDAQ Kamada |
-1.94% | 25.9% | -9.16% | 26.6 | 24 | 0.96 | 80.4% | 43% |
ERF PA Eurofins Scientific SE |
15.4% | 0.42% | 17.2% | 26.6 | 13.6 | 0.56 | -67.4% | -17.7% |
BMRN NASDAQ Biomarin Pharmaceutical |
-7.7% | -24.7% | -30.6% | 28.6 | 15.9 | 0.43 | 67.5% | 59.7% |
Performance Comparison: GMAB vs XBI vs S&P 500
XBI (SPDR S&P Biotech ETF) is the Sector Benchmark for GMAB
Total Return (including Dividends) | GMAB | XBI | S&P 500 |
---|---|---|---|
1 Month | 12.17% | 5.55% | -0.45% |
3 Months | 9.52% | -9.75% | -6.29% |
12 Months | -27.20% | -5.39% | 13.04% |
5 Years | -14.47% | -13.20% | 111.82% |
Trend Score (consistency of price movement) | GMAB | XBI | S&P 500 |
1 Month | 92.3% | 70% | 47.5% |
3 Months | -17.3% | -88.1% | -87.3% |
12 Months | -89.1% | -44.4% | 54.3% |
5 Years | -58.3% | -53.6% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XBI | vs. S&P 500 |
1 Month | #85 | 6.26% | 12.7% |
3 Month | #34 | 21.4% | 16.9% |
12 Month | #76 | -23.1% | -35.6% |
5 Years | #47 | -1.46% | -59.6% |
FAQs
Does GMAB Genmab AS outperforms the market?
No,
over the last 12 months GMAB made -27.20%, while its related Sector, the SPDR S&P Biotech (XBI) made -5.39%.
Over the last 3 months GMAB made 9.52%, while XBI made -9.75%.
Over the last 3 months GMAB made 9.52%, while XBI made -9.75%.
Performance Comparison GMAB vs Indeces and Sectors
GMAB vs. Indices GMAB is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | -0.25% | 12.6% | -5.65% | -40.2% |
US NASDAQ 100 | QQQ | -1.17% | 10.3% | -6.36% | -42.2% |
US Dow Jones Industrial 30 | DIA | 0.29% | 15.0% | -4.89% | -36.5% |
German DAX 40 | DAX | 0.11% | 12.4% | -23.7% | -52.2% |
Shanghai Shenzhen CSI 300 | CSI 300 | 3.40% | 15.4% | -1.95% | -32.2% |
Hongkong Hang Seng | HSI | 0.15% | 13.7% | -6.18% | -40.1% |
India NIFTY 50 | INDA | 2.27% | 7.29% | -5.53% | -30.1% |
Brasil Bovespa | EWZ | 1.38% | 9.34% | -11.4% | -20.5% |
GMAB vs. Sectors GMAB is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | -0.40% | 12.8% | -11.6% | -50.7% |
Consumer Discretionary | XLY | -0.28% | 12.8% | -6.82% | -41.9% |
Consumer Staples | XLP | 1.81% | 13.0% | -9.75% | -38.1% |
Energy | XLE | 4.01% | 26.2% | -0.51% | -17.9% |
Financial | XLF | 0.86% | 14.2% | -12.6% | -49.9% |
Health Care | XLV | 2.45% | 16.8% | -0.49% | -26.0% |
Industrial | XLI | -0.57% | 11.9% | -6.69% | -37.9% |
Materials | XLB | 1.56% | 15.4% | 2.19% | -22.8% |
Real Estate | XLRE | -0.14% | 13.3% | -5.81% | -45.6% |
Technology | XLK | -1.81% | 9.74% | -2.70% | -37.6% |
Utilities | XLU | 1.03% | 12.1% | -10.1% | -48.0% |
Aerospace & Defense | XAR | -1.28% | 5.19% | -19.5% | -54.7% |
Biotech | XBI | -0.09% | 6.62% | 9.66% | -21.8% |
Homebuilder | XHB | 1.02% | 14.3% | 9.31% | -21.0% |
Retail | XRT | 0.99% | 13.3% | 0.31% | -25.7% |